News

This might be the year when it becomes clear, perhaps painfully so, whether or not biosimilars can deliver on cost savings expectations.

As the opioid epidemic rages, doctors and hospitals should consider these tips and strategies employed by other organizations.

More awareness and new state laws regarding end-of-life treatment are affecting treatment approaches. Here’s what you need to know.

More targeted therapies for autoimmune diseases are on the horizon. Here’s what to anticipate in 2018.

The winds of change swept through healthcare in 2017. Here’s what 2018 could bring.

The president and chief executive officer describes the various initiatives the organization is taking, and how they are resulting in big payoffs.

PBMs are in a unique position to help curb opioid abuse. Here are four programs that demonstrate promising outcomes.

Shocking opioid overdose statistics make it crucial to address the epidemic. Here are four programs to watch

By recognizing and address the needs of the “whole person,” we have an opportunity to improve the health of people across the U.S. Here are two ways to do that.

New blockbuster drugs to treat various conditions are expected to be among the top drugs to hit the marketplace in 2018. Here are 5 of the top new drugs in the pipeline for 2018, according to analysts.

Fifty percent of Americans have high blood pressure, per new guidelines. Here’s how those guidelines could affect medication utilization and healthcare spending.

Successful community initiatives are creating systems of care that bridge multiple programs to provide coordinated services to individuals with substance use disorders. Here are five.

The adoption of blockchain in healthcare billings and payments can bring a number of benefits to both payers and providers.

Here’s your quick guide to understanding how CAR T-cell therapy could affect patients and payers.

FDA expanded the indication on cabozantinib (Cabometyx, Exelixis) to treat patients with advanced renal cell carcinoma (RCC).

New TransUnion analysis explores millennial healthcare payment behavior.

Overprescribing by just one practitioner can lead to an untoward outcome that may readily affect the entire healthcare facility.

As 2017 comes to a close, how do healthcare leaders feel about the state of the industry? Here’s your chance to find out.

Simple strategies can improve the nutritional well-being of COPD patients and help them maintain their weight.

From identifying must-read books to exploring how policy changes will affect the industry, Managed Healthcare Executive's most popular articles this year shed light on the biggest areas of interest to managed care organizations.

A Walgreens study sheds light on the benefits of patient-centered pharmacy-based programs.

Insiders unmask what policy actions will continue and what will develop in the next year.

FDA okays the first short-acting insulin approved as a “follow-on” product.

Prepare for major pipeline developments in diabetes, autoimmune disorders, oncology, and COPD.

The Innovation and Value Initiative's Mark Linthicum talks to Managed Healthcare Executive (MHE) a new tool to better measure value in healthcare treatments.

The Innovation and Value Initiative launched the Open-Source Value Project, creating tools that help payers, providers, and healthcare systems make informed and patient-centered decisions that produce better health outcomes.

A new study reveals interesting findings about improving the health of pediatric asthma patients and integrated care programs.